- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01522378
Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging
Cardiac Resynchronization and MIBG Imaging
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The Specific Aim #1 of this study is to assess, with 123iodine metaiodobenzylguanidine (123I-MIBG imaging), whether cardiac resynchronization therapy (CRT) rebalances and improves the integrity and function of sympathetic nerve terminals in the failing myocardium. The study will test the hypothesis that resynchronization of biventricular contractility attenuates excessive sympathetic drive, and improves autonomic function and cardiac performance.
The Specific Aim #2 of this study is to determine the relationship between 123I-MIBG labeling of sympathetic activity and physiological measures of cardiopulmonary and autonomic function. This aim is to test the hypothesis that impaired cardiac sympathetic activity, determined by 123I-MIBG imaging will be associated with poorer submaximal exercise gas exchange (higher ventilation - carbon dioxide (CO2) slopes, low end tidal CO2, reduced oxygen pulse and a more rapid frequency response) as well as reduced heart rate power spectral frequencies, a blunted response to positional changes and a delayed heart rate recovery.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria: Indications for Biv-ICD implantation
- Chronic moderate to severe congestive heart failure (CHF) (NYHA class II or IV)
- Left ventricular ejection fraction (LVEF) of 35% or less
- Q wave, R wave and S wave (QRS complex) QRS duration of 120 ms or more
- On optimized anti-heart failure medical regimen
Meet one of the following indications for ICD
- Survivors of cardiac arrest due to ventricular fibrillation (VF) or ventricular tachycardia (VT) or spontaneous sustained VT
- Nonsustained VT with coronary disease, prior myocardial infarction, LVEF 35% or less, and inducible VF or sustained VT at electrophysiologic study
- LVEF of 30% or less with severe coronary artery disease
Exclusion criteria:
- Patient condition is unstable
- Patient is unable to give informed consent
- Not feasible for patient to be followed at Mayo Clinic
- Female in pregnancy and breast feeding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Biv-ICD
Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
|
10 millicurie (mCi) (370 MBq)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in 123I-MIBG parameters
Tidsramme: baseline, 6 months
|
changes in 123I-MIBG parameters with cardiac performance including LVEF, stroke volume (SV), left ventricle (LV) and left atrium (LA) dimension, distance of 6-minute walk, NYHA class, and ventricular arrhythmic burden
|
baseline, 6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in submaximal exercise gas exchange
Tidsramme: baseline, 6 months
|
Subjects will perform simplified low intensity cardiopulmonary exercise testing in our laboratory where they breathe for 1 min at rest, perform graded step exercise, increasing from 60, 90, 120 steps per minute until achieving a perceived exertion of 12-14 on the 6-20 Borg scale.
This will be followed by a 1 min recovery.
Subjects will be instrumented with ECG, pulse oximeter and breathe on a mouthpiece where ventilation, oxygen and carbon dioxide are measured continuously to calculate the desired parameters of ventilatory efficiency (VE/VCO2), PetCO2 and oxygen pulse (O2Pulse) on a breath by breath basis.
|
baseline, 6 months
|
Change in Autonomic function
Tidsramme: baseline, 6 months
|
In addition to the simplified submaximal step test, subjects will also perform a simplified battery of tests for autonomic function.
This will include supine to upright measures of heart rate and heart rate variability (HRV), paced breathing (slow to faster frequencies) as well as tracking HRV and responses to the increased metabolic demands of exercise and into recovery.
|
baseline, 6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Yongmei Cha, MD, Mayo Clinic
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 11-006296
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kongestiv hjertesvigt
-
Region SkaneTilmelding efter invitationHjertesvigt New York Heart Association (NYHA) klasse II | Hjertesvigt New York Heart Association (NYHA) klasse IIISverige
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... og andre samarbejdspartnereIkke rekrutterer endnuHjertesvigt, systolisk | Hjertesvigt med reduceret udstødningsfraktion | Hjertesvigt New York Heart Association Klasse IV | Hjertesvigt New York Heart Association Klasse IIIPolen
-
University of WashingtonAmerican Heart AssociationAfsluttetHjertesvigt, Kongestiv | Mitokondriel ændring | Hjertesvigt New York Heart Association Klasse IVForenede Stater
-
Novartis PharmaceuticalsAfsluttetPatienter, der med succes afslutter den 12-måneders behandlingsperiode i kernestudiet (de Novo Heart-modtagere), som var interesserede i at blive behandlet med EC-MPS
-
University Hospital, GasthuisbergUkendtTransient Left Ventricular Ballooning SyndromeBelgien
-
NYU Langone HealthRekrutteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeForenede Stater
-
French Cardiology SocietyAfsluttet
Kliniske forsøg med 123 iodine metaiodobenzylguanidine
-
University of PittsburghGE HealthcareAfsluttetStress-induceret kardiomyopatiForenede Stater
-
Institute for Neurodegenerative DisordersAfsluttetAlzheimers sygdomForenede Stater
-
Molecular Insight Pharmaceuticals, Inc.Afsluttet
-
Bausch Health Americas, Inc.AfsluttetAcne VulgarisForenede Stater, Canada
-
Bausch Health Americas, Inc.AfsluttetAcne VulgarisForenede Stater, Canada
-
Oregon Center for Applied Science, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development...Afsluttet
-
University of FloridaAfsluttetRygmarvsskaderForenede Stater
-
Asahi Kasei Pharma CorporationAfsluttetDissemineret intravaskulær koagulationJapan
-
Wisconsin Institute for Neurologic and Sleep Disorders...GE Healthcare; Medical College of Wisconsin; Wisconsin Parkinson AssociationUkendtParkinsons sygdom | BevægelsesforstyrrelserForenede Stater
-
Alseres Pharmaceuticals, IncUkendt